MedPath

Intraoperative Clonidine for Postoperative Pain Management in Patients Undergoing Surgical Treatment for Endometriosis

Phase 4
Completed
Conditions
Endometriosis
Pain, Acute
Postoperative Pain
Pain, Acute Postoperative
Interventions
Drug: Isotonic saline
Registration Number
NCT05560230
Lead Sponsor
University of Aarhus
Brief Summary

The role of a single dose of intraoperative clonidine on postoperative opioid requirements, pain intensity and opioid-related side effects in patients undergoing surgical treatment for endometriosis remains scarcely explored. A prospective double-blind, randomised controlled trial investigating the effect of a single-dose of intraoperative clonidine in patients undergoing surgical treatment for endometriosis is therefore conducted.

Detailed Description

Background with aim: Acute postoperative pain is a major and common concern for the large number of patients who undergo surgery each year. Despite advances in pain management strategies, many patients continue to suffer from moderate-to-severe pain during the early postoperative period. This is concerning as unrelieved pain can result in decreased patient satisfaction, increased morbidity, prolonged hospital length-of-stay and increased risk of persistent pain. Effective treatment of acute postoperative pain should therefore be prioritized. Opioid analgesics remain the mainstay treatment for postoperative pain. The potential benefits of opioid therapy for acute pain are short-term pain control. However, there are several potential harms associated with opioid use which may outweigh the benefits including sedation, nausea, vomiting, constipation and risk of long-term use. In this respect, a single dose of clonidine could provide stable analgesia and potentially reduce the need for shorter-acting opioids. Therefore, the investigators decided to carry out the present study with the aim to examine the analgesic efficacy and safety of intraoperatively administered intravenous clonidine in patients undergoing surgical treatment for endometriosis on postoperative opioid consumption, pain intensity and opioid-related side effects.

Method: 120 patients undergoing surgical treatment for endometriosis will be included in this prospective, randomized, double-blind, controlled trial with two arms: an intervention arm (clonidine 150 microgram) and a control arm (isotonic saline). The study will be GCP-monitored, and is approved by the Danish Medicines Agency (2022064017) and the National Committee on Health Research Ethics (2209269).

Hypothesis: The investigators hypothesize that a single dose of intraoperatively administered intravenous clonidine will be effective in reducing postoperative opioid requirements, pain intensity and opioid-related side effects.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
120
Inclusion Criteria

• Patients scheduled for surgical laparoscopic treatment of endometriosis at Aarhus University Hospital

Exclusion Criteria
  • Age < 18 years
  • American Society of Anesthesiologists (ASA) physical status IV or V
  • Allergy to clonidine
  • Inability to provide informed consent
  • Known severe renal insufficiency
  • Known severe bradyarrhythmia
  • Pregnancy, lactation:
  • Daily opioid consumption the last 7 days before surgery
  • Pain intensity >5 on more than half of the days during the last month

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Isotonic salineIsotonic salineA 100 ml isotonic saline will be mixed with 1 ml isotonic saline. The blinded 100 ml bag including isotonic saline will be infused over 5-10 min., immediately after intubation.
ClonidineClonidineA 100 ml isotonic saline will be mixed with 1 ml clonidine (150 μg). The blinded 100 ml bag including isotonic saline and clonidine 150 μg will be infused over 5-10 min., immediately after intubation.
Primary Outcome Measures
NameTimeMethod
Cumulative opioid consumption 0-3 hours3 hours after arrival at the PACU

Opioid consumption within the first 3 hours after arrival at the PACU

Secondary Outcome Measures
NameTimeMethod
Shivering0, 60 and 120 minutes after arrival at the PACU

Shivering at 0, 60 and 120 minutes after arrival at the PACU

Cumulative opioid consumption 0-6 hours6 hours after arrival at the PACU

Opioid consumption within the first 6 hours after arrival at the PACU

Pain intensity during coughing0, 30, 60, 90 and 120 minutes after arrival at the PACU

Pain intensity during coughing at 0, 30, 60, 90 and 120 minutes after arrival at the PACU

Pain intensity at rest0, 30, 60, 90 and 120 minutes after arrival at the PACU

Pain intensity at rest (NRS; 0-10) at 0, 30, 60, 90 and 120 minutes after arrival at the PACU

Sedation (Ramsey Sedation Score 1-6)0, 60 and 120 minutes after arrival at the PACU

Sedation at 0, 60 and 120 minutes after arrival at the PACU

PONV0, 60 and 120 minutes after arrival at the PACU

Nausea and/or vomiting at 0, 60 and 120 minutes after arrival at the PACU

Discharge from the PACU24 hours

Time for discharge from the PACU (hours and minutes)

Trial Locations

Locations (1)

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath